- Home
- CLVT vs JANX Comparison
CLVT vs JANX Comparison
Compare CLVT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLVT
- JANX
- Stock Information
- Founded
- CLVT 2016
- JANX 2017
- Country
- CLVT United Kingdom
- JANX United States
- Employees
- CLVT N/A
- JANX N/A
- Industry
- CLVT EDP Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- CLVT Technology
- JANX Health Care
- Exchange
- CLVT Nasdaq
- JANX Nasdaq
- Market Cap
- CLVT 2.8B
- JANX 1.4B
- IPO Year
- CLVT N/A
- JANX 2021
- Fundamental
- Price
- CLVT $4.34
- JANX $25.15
- Analyst Decision
- CLVT Hold
- JANX Strong Buy
- Analyst Count
- CLVT 3
- JANX 8
- Target Price
- CLVT $5.00
- JANX $90.63
- AVG Volume (30 Days)
- CLVT 5.9M
- JANX 711.6K
- Earning Date
- CLVT 07-30-2025
- JANX 08-06-2025
- Dividend Yield
- CLVT N/A
- JANX N/A
- EPS Growth
- CLVT N/A
- JANX N/A
- EPS
- CLVT N/A
- JANX N/A
- Revenue
- CLVT $2,529,200,000.00
- JANX $9,336,000.00
- Revenue This Year
- CLVT N/A
- JANX N/A
- Revenue Next Year
- CLVT $0.25
- JANX $1,470.82
- P/E Ratio
- CLVT N/A
- JANX N/A
- Revenue Growth
- CLVT N/A
- JANX 28.12
- 52 Week Low
- CLVT $3.04
- JANX $22.48
- 52 Week High
- CLVT $7.15
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- CLVT 49.76
- JANX 54.41
- Support Level
- CLVT $4.33
- JANX $23.52
- Resistance Level
- CLVT $4.57
- JANX $24.87
- Average True Range (ATR)
- CLVT 0.20
- JANX 1.13
- MACD
- CLVT 0.01
- JANX 0.33
- Stochastic Oscillator
- CLVT 56.92
- JANX 70.90
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.